Amgen/AMGN
$312.47
-0.71%-
1D1W1MYTD1YMAX
About Amgen
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
Ticker
AMGN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Robert Bradway
Employees
26,700
Headquarters
Thousand oaks, United States
Website
www.amgen.com
Amgen Metrics
BasicAdvanced
$171B
Market cap
45.59
P/E ratio
$7.00
EPS
0.62
Beta
$8.64
Dividend rate
2.82%
Dividend yield
Price and volume
Market cap
$171B
Beta
0.61598
52-week high
$329.72
52-week low
$211.71
Average daily volume
2.8M
Dividend rate
$8.64
Financial strength
Current ratio
1.422
Quick ratio
0.979
Long term debt to equity
1,195.958
Total debt to equity
1,274.791
Dividend payout ratio (TTM)
125.27%
Enterprise value to free cash flow
83.256
Interest coverage (TTM)
2.46%
Management effectiveness
Return on assets (TTM)
4.14%
Return on equity (TTM)
72.57%
Return on investment (TTM)
5.09%
Valuation
Price to earnings (TTM)
45.588
Price to revenue (TTM)
5.795
Price to book
34.077
Price to free cash flow (TTM)
69.261
Five year average dividend yield
2.85%
Dividend yield (TTM)
2.71%
Forward dividend yield
2.82%
Growth
Revenue change (TTM)
12.76%
Earnings per share change (TTM)
-52.46%
3-year revenue growth
3.5%
3-year earnings per share growth
0.47%
3-year dividend per share growth
10.01%
What the Analysts think about Amgen
Analyst Ratings
Majority rating from 31 analysts.
Price Targets
Average projection from 23 analysts.
High $380.00
Low $170.00
$312.47
Current price
$316.85
Average price target
Amgen Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$7.4B
-9.14%
Net income
-$113M
-114.73%
Profit margin
-1.51%
-116.15%
Amgen Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$5.00
$4.96
$4.71
$3.96
-
Expected
$4.49
$4.67
$4.61
$3.87
$4.97
Surprise
11.3%
6.16%
2.27%
2.32%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for Amgen stock?
Amgen (AMGN) has a market cap of $168B as of May 20, 2024.
What is the P/E ratio for Amgen stock?
The price to earnings (P/E) ratio for Amgen (AMGN) stock is 44.65 as of May 20, 2024.
Does Amgen stock pay dividends?
Yes, the Amgen (AMGN) stock pays dividends to shareholders. As of May 20, 2024, the dividend rate is $8.64 and the yield is 2.88%. Amgen has a payout ratio of 125.27% on a trailing twelve-month basis.
When is the next Amgen dividend payment date?
The next Amgen (AMGN) dividend payment is scheduled for June 07, 2024.
What is the beta indicator for Amgen?
Amgen (AMGN) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
What is the Amgen stock price target?
The target price for Amgen (AMGN) stock is $316.85, which is 1.4% above the current price of $312.47. This is an average based on projections from 23 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell Amgen stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.